Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Culture

19 Oct 2024

Real-Life Fungi in Fiction: The Origins of ‘Bliss’ in The Penguin

Derived from the real-life Bleeding Tooth Fungus (Hydnellum peckii), Bliss is portrayed as a euphoric stimulant, manufactured in underground labs. While the fungus’ crimson fluid looks sinister, it isn't psychoactive....

By Microdose NewsDesk

Breaking News

10 Sep 2024

Mindstate Design Labs AI-Designed Trial Gets FDA Approval

Mindstate Design Labs has announced major news, receiving both FDA and European Medicines Agency (EMA) approval to commence human trials of its compound, MSD-001. This approval is a clinical validation...

By Microdose NewsDesk
cybin deal

Breaking News

6 Sep 2024

Psyence Biomed Announces Acquisition of Psilocybin Drug Developer Clairvoyant Therapeutics

Psyence Biomed announces acquisition Clairvoyant Therapeutics and its Phase 2b trial...

By Microdose NewsDesk

Science

30 May 2024

Interview with Terran’s CEO Sam Clark on Terran’s pipeline, including “TerXT” for schizophrenia, a new competitor to Karuna’s KarXT

We sat down with Sam Clark, CEO of Terran Biosciences, to discuss the exciting developments in their pipeline, particularly their latest schizophrenia therapeutic, TerXT. This new treatment is designed to...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News

26 Feb 2024

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2A Take-Home Microdosing Trial

MindBio Therapeutics has announced groundbreaking results from a Phase 2a clinical trial involving the take-home microdosing of MB22001 for treating depression. This world-first trial showcased a significant decrease in depression...

By Microdose NewsDesk

Industry

20 Dec 2023

Terran Biosciences Receives FDA Clearance for MRI Scan Technology

Terran Biosciences Receives FDA Clearance for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI...

By Microdose NewsDesk
news

Don’t Miss

18 Dec 2023

News You Might Have Missed: Dec 18th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk

Science

14 Dec 2023

MindMed Announces Positive Results from Phase 2b Anxiety Trial

Big news as the trial met its primary endpoint, with 50% clinical remission rate at Week 4....

By Microdose NewsDesk
maps

Breaking News

12 Dec 2023

Breaking News: MAPS Files New Drug Application With FDA for MDMA-Assisted Therapy

Historic filing marks first New Drug Application submission for any psychedelic-assisted therapy....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.